Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
S-1 + irinotecan + oxaliplatin
- Development stage
- Unknown
- Lead developer
- National Cancer Center Korea
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
TIROX is a triplet chemotherapy regimen combining three active cytotoxic agents: S-1 (an oral fluoropyrimidine), irinotecan (a topoisomerase I inhibitor), and oxaliplatin (a platinum-based agent). Developed and studied by the National Cancer Center in Korea, this combination is primarily investigated for the treatment of advanced or metastatic gastrointestinal malignancies, including colorectal and gastric cancers. S-1 is a multi-component drug consisting of tegafur (a 5-fluorouracil prodrug), gimeracil (a dihydropyrimidine dehydrogenase inhibitor), and oteracil potassium (which reduces gastrointestinal toxicity). Irinotecan works by inhibiting DNA topoisomerase I, preventing DNA religation and causing double-strand breaks, while oxaliplatin forms DNA cross-links that inhibit replication and transcription. Clinical trials have demonstrated high objective response rates, particularly in gastric cancer, with a manageable safety profile.
- Other names
- TIROX regimenS-1/irinotecan/oxaliplatin
02
Targets
TOP1 (DNA Topoisomerase I)DPYD (Dihydropyrimidine dehydrogenase)DNATS (Thymidylate synthase)OPRT (Orotidine 5'-phosphate decarboxylase)
Beyond the preview
Go deeper on S-1 + irinotecan + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on S-1 + irinotecan + oxaliplatin.